BCAB - CIK 0001826892
The table below shows BioAtla, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$48.20M | -$71.94M | -$104.02M | -$90.42M | -$62.21M | -$36.33M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | - | $0.00 | -$98.00K | -$265.00K | -$924.00K | -$590.00K |
| Dividends paid | - | - | - | - | - |
BioAtla, Inc. reported operating cash flow of -$48.20M for fiscal year 2025. That is up 33.0% from -$71.94M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$9.64M (FY 2019) to -$48.20M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $6.28M | $9.51M | $77.00K | $61.21M | $69.51M | $271.82M |